Alexion Pharma (ALXN) Tops Q4 EPS by 1c; Guides Below the Street, $1B Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017
February 16, 2017 6:30 AM ESTTotal Revenues of $3.084 Billion, an 18% Increase Over 2015 and 22% Volume Increase Global Soliris® Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Strensiq® and Kanuma® Global Launches Progress With New Patients Starting on Treatment Filed Regulatory Submissions for Soliris in Patients with Refractory gMG in the U.S. and Europe ALXN1210 Phase 3 Studies Underway in Patients with PNH and aHUS Alexion Board Increases Authorized Share Repurchase to a Total of $1 Billion... More
